Continuous glucose monitors

Guardian™ Connect continuous glucose monitoring system

<p>Guardian™ Connect is a continuous glucose monitoring (CGM) system that can alert patients up to 60 minutes in advance of a high or low glucose excursion.</p>

Features

Performance and accuracy for low detection1 so your patients can live more and worry less


Intelligence at your patients’ fingertips so they feel in control

The Guardian™ Connect CGM system can alert your patients 30 minutes sooner than other products, giving your patients more time to react and get ahead of high and low glucose levels.

In a CareLink™ data analysis of real-world data,2 it was found that Guardian™ Connect system users avoided 65% of lows and 44% of high glucose episodes.

 

40%

of people with type 1 diabetes experience hypoglycemia unawareness3

 

49%

of people with type 2 diabetes experience one episode of hypoglycemia in 5 days4

 

98%

Low detection accuracy with predictive alerts turned on1

Guardian™ Connect system overview

Helps patients see the full picture

Patients can view their current glucose level and trend direction instantly. Glucose levels are updated every five minutes.

Patients can easily track exercise, meals, insulin doses and other important events to see how their glucose levels are impacted.

Glucose readings and events for the past few hours, days, or months. Patients can view history up to three months prior.

Small and discreet wireless transmitter sends glucose readings directly to your patient's smartphone.

Measures glucose levels every five minutes.

Components of the Guardian™ Connect system

* Smart CGM predicts future high and low sensor glucose events up to 60 minutes in advance.

† Other CGM's provide predictive alerts up to 30-minutes per respective user guides.

‡ Low episodes defined as ≤ 70 mg/dL in sensor glucose level; high episode as ≥ 180 mg/dL in sensor glucose level.

  1. Guardian™ Connect SSED, page 19, Table 5. 98.5% Glucose Correct Detection Rate based on Predictive Alerts at 30 minutes when worn on the abdomen; Data includes all US patients uploading voluntarily to CareLink™ Personal software from June 2018 to Feb 2019  N=802. Patients included might be on other diabetes therapy, including insulin pumps, multiple daily injections or oral medications.
  2. Arunachalam S, et al. Poster presented at ADA 2019. 79th Scientific Sessions. June 7th-11th. San Francisco, California. #939-P; Data includes all US patients uploading voluntarily to CareLink™ Personal Software from June 2018 to Feb 2019 N=802. Patients included might be on other diabetes therapy, including insulin pumps, multiple daily injections or oral medications
  3. Martín-Timón, Cañizo-Gómez. Diabetes. 2015;6(7):912. 
  4. Gehlaut, Richa R., et al. J Diab Science Tech. 2015;9(5):999-1005.